AstraZeneca to Showcase Extensive Oncology and Rare Disease Data at ASCO 2026

AstraZeneca will present new late-stage clinical results in various types of cancer and a rare hematological disease at the 2026 American Society of Clinical Oncology Annual Meeting (ASCO 2026), reinforcing its commitment to bringing innovative therapies to earlier stages of disease and expanding therapeutic options in oncology and rare diseases.

The company will present more than 85 abstracts at the congress, which will be held from May 29th to June 2nd, with results related to 10 already approved drugs and 13 potential new drugs. These include trials in liver, breast, and bladder cancer, as well as data on a potential antifibrillary therapy for amyloidosis.

Relevant results from clinical trials

One of the most relevant studies will be EMERALD-31, a Phase III trial evaluating durvalumab in combination with tremelimumab, with or without lenvatinib, along with transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma eligible for embolization. The presentation, categorized as late-breaking, will analyze the potential clinical benefit of this combination in earlier-stage liver cancer.

In metastatic breast cancer, AstraZeneca will present new results from several Phase III studies. Among them, SERENA-62 will provide final data on progression-free survival and clearance of circulating tumor DNA linked to long-term efficacy in patients with HR-positive, HER2-negative advanced breast cancer with emerging ESR1 mutations treated with camizestrant and CDK4/6 inhibitors.

New analyses from the DESTINY-Breast093 trial will also be presented, evaluating trastuzumab deruxtecan combined with pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer. The data will explore treatment duration and clinical outcomes based on the type of response achieved.

Furthermore, the TROPION-Breast024 study will show additional efficacy results of datopotamabderuxtecan in patients with locally recurrent or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitors.

The conference will also include results from the CARES5 program, a Phase III trial led by Alexion, focusing on anselamimab, a potential antifibrillary therapy for newly diagnosed patients with AL light chain amyloidosis. The results will include a specific analysis based on the kappa or lambda free light chain subtype.

Positive results for AstraZeneca

According to the company, the data will show a “highly significant” clinical benefit in patients with AL kappa amyloidosis, a rare disease in which amyloid deposits damage vital organs.

Among the new developments are also initial results from therapies and molecules in early development. AstraZeneca will present data from PRIMAVERA, the first human trial of the PRMT5 inhibitor AZD3470 in relapsed or refractory classical Hodgkin lymphoma, as well as preliminary results from NT-1758, a T-cell receptor therapy targeting advanced solid tumors with the TP53 R175H mutation.

Additionally, the results of the BLUESTAR trial with puxitatugsamrotecan, an antibody-drug conjugate targeting B7-H4 in metastatic ovarian and endometrial cancer, will be updated. This treatment recently received Breakthrough Therapy designation from the Food and Drug Administration.

In bladder cancer, the POTOMAC trial will provide five-year results on overall survival and quality of life reported by patients treated with durvalumab combined with Bacillus Calmette-Guérin (BCG) in high-risk non-muscle-invasive bladder cancer.

Susan Galbraith , executive vice president of R&D in Oncology and Hematology at AstraZeneca, stated that the data to be presented at ASCO “advances our strategy to redefine patient outcomes,” and underscored the transformative potential of new breast cancer treatments and new therapeutic modalities under development.

The executive also highlighted the first clinical results for the NT-175 T-cell receptor therapy and the PRMT5 inhibitor AZD3470, as well as updated data for the antibody-drug conjugate puxitatugsamrotecan. “Taken together, these data reinforce the strength and depth of our oncology portfolio,” she noted.

Dave Fredrickson , executive vice president of AstraZeneca’s Oncology and Hematology Business Unit, said that the EMERALD-31 data “exemplify our strategy of moving immunotherapy regimens to earlier stages of cancer where we could further improve outcomes for patients.”

Fredrickson added that the company has obtained more than a dozen approvals in various oncology indications for five different drugs in the last six months, which, he said, demonstrates “the quality of our innovation and the strength of our business.”

From Alexion, Gianluca Pirozzi, Director of Development, Regulation, and Safety, explained that the CARES5 results highlight the potential of anselamimab as a “first-class antifibrillary therapy” for patients with AL kappa amyloidosis. He elaborated that the treatment is designed to target and eliminate amyloid deposits in affected organs, with the aim of prolonging survival and reducing cardiovascular hospitalizations.

In Spain, Ana Peiró, Medical Director of Oncology at AstraZeneca, highlighted that the high number of results presented at ASCO “reflects the scope and strength” of the company’s research program. “Driven by research and innovation, we continue working to transform the approach to and treatment of cancer, both in early and advanced stages,” she stated.

AstraZeneca also maintains collaboration agreements with Daiichi Sankyo for the development and commercialization of trastuzumabderuxtecan and datopotabderuxtecan.

__

(Featured image by Mika Baumeister via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in GACETA MEDICA. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.